Morgan Stanley Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $69

摩根士丹利维持Biohaven(BHVN.US)买入评级，维持目标价69美元

moomoo资讯 · 2024/11/15 21:31 · 评级/大行评级

Morgan Stanley analyst Terence Flynn maintains $Biohaven (BHVN.US)$ with a buy rating, and maintains the target price at $69.

According to TipRanks data, the analyst has a success rate of 52.3% and a total average return of 7.2% over the past year.

AnalystRecentRatingAutoNews_74217035088037_20241115_c580efca8787d61123ba14589e335a874ba18e85_1731709815921620_mm_en

Furthermore, according to the comprehensive report, the opinions of $Biohaven (BHVN.US)$'s main analysts recently are as follows:

The firm's reduction in the valuation of Biohaven is influenced by the company's operating expenses surpassing forecasts for Q3, coupled with the effects of the recent capital increase. Nevertheless, Biohaven is anticipated to stay on course for significant developmental milestones expected to be announced before the year concludes.
The expectation is set for Biohaven's Phase III data for T-alfa in SMA to present a favorable risk/reward profile. As the year progresses, anticipation builds for the updated data on the SAD/MAD/subQ IgG degrader for BHV-1300, as well as the planned IND submissions for three more candidates from the MoDE degrader platform.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

摩根士丹利分析师Terence Flynn维持$Biohaven (BHVN.US)$买入评级，维持目标价69美元。

根据TipRanks数据显示，该分析师近一年总胜率为52.3%，总平均回报率为7.2%。

AnalystRecentRatingAutoNews_74217035088037_20241115_c580efca8787d61123ba14589e335a874ba18e85_1731709815921620_mm_sc

此外，综合报道，$Biohaven (BHVN.US)$近期主要分析师观点如下：

该公司降低Biohaven估值受该公司运营支出超过第三季度预期的影响，再加上最近增资的影响。尽管如此，预计Biohaven将继续朝着重要的发展里程碑迈进，预计将在今年年底之前公布。
预计Biohaven的SMA中t-alfa的第三阶段数据将呈现良好的风险/回报状况。随着时间的推移，人们对 BHV-1300 SAD/MAD/SubQ IgG 降解剂的最新数据以及计划从 MoDe 降解剂平台提交另外三份候选药物的 IND 申请的期望越来越高。

提示:

TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。

TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。

分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。

总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Morgan Stanley Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $69

Morgan Stanley Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $69

风险及免责提示

声明